Sofosbuvir (Sovaldi) for the treatment of hepatitis C

被引：24

作者：

Lam, Brian ^{[1
]}

Henry, Linda ^{[1
]}

Younossi, Zobair ^{[2
]}

机构：

[1] Betty & Guy Beatty Liver & Obes Res Program, Falls Church, VA 22042 USA

[2] Inova Fairfax Hosp, Inova Hlth Syst, Beatty Ctr Integrated Res, Dept Med, VCU Inova Campus,3300 Gallows Rd, Falls Church, VA 22042 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2014年 / 7卷 / 05期

关键词：

7977; interferon; ION; ledipasvir; Sovaldi; SUSTAINED VIROLOGICAL RESPONSE; VIRUS-INFECTION; PERSONS BORN; HCV; RIBAVIRIN; ABT-450/R-OMBITASVIR; INTERFERON; BOCEPREVIR; TELAPREVIR; DASABUVIR;

D O I：

10.1586/17512433.2014.928196

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hepatitis C (HCV) remains an important cause of chronic liver disease worldwide. Historically, treatment included pegylated-interferon and ribavirin with low efficacy and numerous side effects contributing to poor adherence and impairment of patients' well-being. The next step in developing better treatment regimens for HCV led to the development of the first-generation direct acting antivirals (DAAs). Although these DAAs improved efficacy, they also added substantial side effects. The next generation of DAAs include Simeprevir and Sofosbuvir (SOF) which not only further enhanced the efficacy of the regimens but also improve their safety profile. This review summarizes the current clinical experience with SOF. SOF, an HCV-specific uridine nucleotide analog which inhibits the NS5B polymerase, is now available in the USA, Canada and Europe. Clinical trials of SOF-containing regimens have shown that these regimens are safe, efficacious, and well-tolerated in all genotypes. Additionally, SOF is associated with improved patient reported outcomes.

引用

页码：555 / 566

页数：12

共 50 条

[1] The new paradigm of hepatitis C therapy: integration of oral therapies into best practices [J].

Afdhal, N. H. ;

Zeuzem, S. ;

Schooley, R. T. ;

Thomas, D. L. ;

Ward, J. W. ;

Litwin, A. H. ;

Razavi, H. ;

Castera, L. ;

Poynard, T. ;

Muir, A. ;

Mehta, S. H. ;

Dee, L. ;

Graham, C. ;

Church, D. R. ;

Talal, A. H. ;

Sulkowski, M. S. ;

Jacobson, I. M. .

JOURNAL OF VIRAL HEPATITIS, 2013, 20 (11) :745-760

[2] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Zeuzem, Stefan ;

Kwo, Paul ;

Chojkier, Mario ;

Gitlin, Norman ;

Puoti, Massimo ;

Romero-Gomez, Manuel ;

Zarski, Jean-Pierre ;

Agarwal, Kosh ;

Buggisch, Peter ;

Foster, Graham R. ;

Braeu, Norbert ;

Buti, Maria ;

Jacobson, Ira M. ;

Subramanian, G. Mani ;

Ding, Xiao ;

Mo, Hongmei ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Mangia, Alessandra ;

Marcellin, Patrick .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898

[3] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Reddy, K. Rajender ;

Nelson, David R. ;

Lawitz, Eric ;

Gordon, Stuart C. ;

Schiff, Eugene ;

Nahass, Ronald ;

Ghalib, Reem ;

Gitlin, Norman ;

Herring, Robert ;

Lalezari, Jacob ;

Younes, Ziad H. ;

Pockros, Paul J. ;

Di Bisceglie, Adrian M. ;

Arora, Sanjeev ;

Subramanian, G. Mani ;

Zhu, Yanni ;

Dvory-Sobol, Hadas ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

Kwo, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493

[4] Mongolia's struggle with liver cancer [J].

Alcorn, Ted .

LANCET, 2011, 377 (9772) :1139-1140

[5]

[Anonymous], 2013, CLIN GASTROENTEROL H

[6] The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].

Armstrong, Gregory L. ;

Wasley, Annemarie ;

Simard, Edgar P. ;

McQuillan, Geraldine M. ;

Kuhnert, Wendi L. ;

Alter, Miriam J. .

ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714

[7] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[8] Projected future increase in aging hepatitis C virus-infected liver transplant candidates: A potential effect of hepatocellular carcinoma [J].

Biggins, Scott W. ;

Bambha, Kiran M. ;

Terrault, Norah A. ;

Inadomi, John ;

Shiboski, Stephen ;

Dodge, Jennifer L. ;

Gralla, Jane ;

Rosen, Hugo R. ;

Roberts, John P. .

LIVER TRANSPLANTATION, 2012, 18 (12) :1471-1478

[9] Hepatitis C virus infection in USA: an estimate of true prevalence [J].

Chak, Eric ;

Talal, Andrew H. ;

Sherman, Kenneth E. ;

Schiff, Eugene R. ;

Saab, Sammy .

LIVER INTERNATIONAL, 2011, 31 (08) :1090-1101

[10] Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies [J].

Chen, Jianmeng ;

Florian, Jeffry ;

Carter, Wendy ;

Fleischer, Russell D. ;

Hammerstrom, Thomas S. ;

Jadhav, Pravin R. ;

Zeng, Wen ;

Murray, Jeffrey ;

Birnkrant, Debra .

GASTROENTEROLOGY, 2013, 144 (07) :1450-U218

← 1 2 3 4 5 →